{"schema_version":"secwatch.filing_event.v1","accession":"0001628280-25-038855","form_type":"8-K","ticker":"SGMO","cik":"0001001233","company_name":"SANGAMO THERAPEUTICS, INC","filed_at":"2025-08-07T23:59:59+00:00","discovered_at":"2026-05-14T18:02:43.102252+00:00","generated_at":"2026-05-17T16:57:05.012721+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Sangamo reports positive Fabry gene therapy data, Q2 net loss narrows to $20M","bullets":["Positive topline from registrational STAAR study: mean annualized eGFR slope +1.965 at 52 weeks across all 32 dosed Fabry patients; FDA agrees as primary basis for accelerated approval.","BLA submission for isaralgagene civaparvovec expected as early as Q1 2026; business development for Fabry commercialization ongoing.","First clinical site initiated for Phase 1/2 STAND study in chronic neuropathic pain; first patient dosing expected fall 2025, preliminary efficacy data Q4 2026.","Q2 2025 revenue $18.3M (vs $0.3M YoY) driven by Lilly license payment; net loss $20.0M ($0.08 EPS) vs $36.1M ($0.18 EPS) prior year.","Cash $38.3M as of June 30; raised ~$21M net from equity offering; expects funding into Q4 2025; reaffirms 2025 opex guidance $135-155M GAAP."],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-25-038855","json":"https://secwatch.observer/filing/0001628280-25-038855.json","markdown":"https://secwatch.observer/filing/0001628280-25-038855.md","text":"https://secwatch.observer/filing/0001628280-25-038855.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1001233/000162828025038855/0001628280-25-038855-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1001233/000162828025038855/sgmo-20250807.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T16:57:05.012721+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}